Noom Med Review 2026: Strong Behavioral Model, Opaque Quarterly Billing

Noom Med is built around an idea that has real clinical backing: weight management outcomes improve when medication is paired with behavioral psychology support. The question is whether the execution earns the premise — and whether the pricing structure allows patients to make an informed decision before committing.

This review covers what Noom Med actually delivers, at what price, and where the model creates friction.

The behavioral layer — the real differentiator

Every Noom Med plan includes the full Noom app, not just a prescription. The behavioral curriculum is built on CBT and DBT principles:

• Daily micro-lessons (10–15 minutes): Psychology of eating, habit formation, trigger identification, emotional eating patterns
• Food logging: Colour-coded by caloric density (green/yellow/red) rather than calorie counting alone
• Mood tracking: Identifies emotional states tied to eating patterns
• Muscle Defense protocol: Structured resistance training designed to preserve lean mass during GLP-1-induced weight loss — a legitimate clinical concern; GLP-1 weight loss includes roughly 30–40% lean mass
• GLP-1 Companion: An app component specific to medication users, covering side effect management and injection scheduling

This is more than what medication-only providers (Ro, Henry Meds, Eden) offer. It is the genuine case for Noom Med. The psychological architecture of eating — food noise, hedonic eating, post-restriction rebound — is real, and a drug-only approach does not address it.

The evidence caveat: Noom claims 48% more weight loss compared to GLP-1 medication alone. This figure comes from retrospective self-reported user data — not a randomised controlled trial. Published Noom studies exist (including a 2022 JMIR study on coaching-only outcomes) but none have specifically studied the combined medication + coaching programme in a controlled design. The claim is plausible; the evidence base supporting the specific number is thin.

What Noom Med actually costs

This is the part that surprises people. The Noom Med pricing page prominently shows:

• Microdose semaglutide: $79 first 4 weeks, then $199/month
• Full-dose semaglutide: $129 first 4 weeks, then $129/month
• Tirzepatide (Plus): $149 first 4 weeks, then $299/month
• Branded telehealth: $69 first month, then $99/month

These are the per-month equivalents of quarterly billing. The actual checkout shows the full quarterly charge:

"I go to sign up for Noom to be hit with tiny print 'Refills are billed $837 every 12 weeks' at the very last step" — documented Reddit complaint with significant engagement. This is the defining friction point in Noom Med's user reviews.

There is no monthly billing option for compounded plans. There are no mid-cycle refunds. Cancellation triggers Noom's well-documented "three discount offers before you can leave" flow.

Noom's history with this: A $56M class-action settlement covering the 2016–2020 cohort addressed exactly this pattern — opaque auto-renewal, difficult cancellation, billing surprises. Noom agreed to enhanced disclosure requirements as part of the settlement. The current reviews suggest the complaint pattern persists in the Med product.

The 503A pharmacy acquisition

On April 1, 2026, Noom acquired Tailor Made Compounding (TMC) — a 503A compounding pharmacy licensed in 46 states. This is a strategically significant move.

Context: After the FDA declared semaglutide shortage resolved in February 2025, the legal basis for large-scale 503B compounding of semaglutide collapsed. Most telehealth compounding operators are operating under §503A patient-specific framing — the "significant difference" argument that a personalised formulation justifies compounding.

By acquiring TMC directly, Noom controls its own 503A pharmacy. This gives it more operational certainty than platforms relying on third-party pharmacy partners that can exit the market (as Hims's pharmacy partners did when Hims settled with Novo Nordisk).

The legal question: Noom's "microdosing" argument — that sub-therapeutic semaglutide doses (max 0.6 mg/week in the Microdose plan) constitute a personalised formulation not commercially available — is legally contested. The FDA treats compounded products within 10% of commercial doses as essentially copies. How this plays out as FDA enforcement activity continues is not settled.

TMC received an FDA warning letter in April 2020 for unapproved drug sales. Those issues were reportedly resolved; nothing new has been cited since 2022. Noom acquired TMC after those compliance matters closed.

Clinical model

Prescribers: Licensed physicians and nurse practitioners with family medicine and internal medicine backgrounds — not ABOM-certified obesity medicine specialists. This is a meaningful step down in clinical specialisation compared to Form Health (ABOM physicians) and, to a lesser degree, Mochi Health. For straightforward GLP-1 prescribing in otherwise healthy patients, this is adequate. For complex clinical presentations, it is a gap.

Visit model: Initial consultation is a 15–20 minute video call or asynchronous intake (varies by plan). Ongoing care is app-primary — monthly check-ins for the first three months, quarterly thereafter. 24/7 in-app messaging with clinician response times of up to 4+ business days reported in reviews.

Phone support: 1-855-NOOM-MED, Monday–Friday 8AM–8PM ET.

Geographic coverage: 46 states. Alabama and Virginia are excluded.

Who Noom Med is right for

Best case — self-directed app users who want the behavioral layer: If you are the kind of person who engages with daily lessons, tracks food in an app, and wants the psychological scaffolding alongside the medication, Noom's model delivers real value that medication-only platforms don't.

Second-best case — patients who want 503A compounded access with more supply certainty: Noom's TMC acquisition gives it more operational stability in the compounded market than platforms relying on third-party pharmacies.

Not the right fit for:

• Patients who expect monthly billing or no-friction cancellation
• Patients who need synchronous physician relationships or specialist clinical oversight (Form Health or Calibrate)
• Insurance-first patients seeking PA support for branded GLP-1s — Calibrate, Mochi, and Ro Body do this more centrally
• Budget-conscious patients — compounded semaglutide at ~$837/quarter is not competitive against Eden ($229/month ongoing) or Mochi ($178/month)

Ratings summary

For the full provider landscape comparison, see GLP-1 provider comparison.